Group One Trading’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Group One Trading’s Portfolio IMUC Stock Details IMUC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-1,785	Closed	-$64K	–	5874
2014 Q3	$64K	Sell	1,785 -633	-26%	-$24.4K	﹤0.01%	3367
2014 Q2	$108K	Sell	2,418 -1,482	-38%	-$71.5K	﹤0.01%	2920
2014 Q1	$190K	Sell	3,900 -60	-2%	-$2.93K	﹤0.01%	2487
2013 Q4	$147K	Buy	3,960 +2,092	+112%	+$198K	﹤0.01%	2704
2013 Q3	$192K	Sell	1,868 -1,540	-45%	-$169K	﹤0.01%	2422
2013 Q2	$264K	Buy	+3,408	New	+$326K	0.01%	1899

Other funds holding IMUC

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Group One Trading's IMUC Position: Q4 2016 in Review

Group One Trading sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2016, closing a stake of 18 shares.

Group One Trading first reported a position in IMUC in Q2 2013 and held it in 11 quarters. The position peaked at $398K in Q3 2013. 16 funds tracked by Wall St. Rank hold IMUC as of Q4 2016.

Group One Trading reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2016 after selling out during the quarter.
Group One Trading sold 18 ImmunoCellular Therapeutics, Ltd. shares in Q4 2016.
Group One Trading first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 11 quarters.
Group One Trading's ImmunoCellular Therapeutics, Ltd. position peaked at $398K in Q3 2013.
16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2016.

Based on Group One Trading's 13F filing for Q4 2016, filed 15 Feb 2017.